Abstract
No public abstract is available from the verified source records.
Open public full textRights: UNKNOWN · http://onlinelibrary.wiley.com/termsAndConditions#vor · Source: journal-auto-sync:external:CROSSREF_ISSN
Paul Cullen, Sotiris Souris, Helmut Schulte, Gerd Assmann
Abstract
Rights: UNKNOWN · http://onlinelibrary.wiley.com/termsAndConditions#vor · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1007/978-1-4614-7524-8_2
10.1007/978-1-4614-7524-8_2
10.1016/s0140-6736(97)90021-0
10.1016/s0140-6736(97)90021-0
10.7326/0003-4819-124-1_part_2-199601011-00011
10.7326/0003-4819-124-1_part_2-199601011-00011
10.1001/archinte.1995.00430010063008
10.1001/archinte.1995.00430010063008
10.1159/000177131
10.1159/000177131
10.2337/diacare.21.1.69
10.2337/diacare.21.1.69
10.1253/jcj.62.414
10.1253/jcj.62.414
10.1001/archinte.146.11.2229
10.1001/archinte.146.11.2229
10.1016/0002-8703(85)90070-5
10.1016/0002-8703(85)90070-5
The impact of diabetes on survival following myocardial‐infarction in men vs
10.1001/jama.1988.03410230074031 · 1988
10.1016/s0002-9149(84)80196-4
10.1016/s0002-9149(84)80196-4
10.1016/0002-9343(84)90277-8
10.1016/0002-9343(84)90277-8
Accelerating impact of diabetes on mortality in the years following an acute myocardial infarction
1998
10.1016/0300-2977(94)00048-e
10.1016/0300-2977(94)00048-e
The prevalence of hyperlipidaemia and related clinical features in insulin‐dependent diabetes mellitus
1989
10.2337/diacare.2.1.31
10.2337/diacare.2.1.31
10.1016/s0002-9149(96)00159-2
10.1016/s0002-9149(96)00159-2
10.1161/01.atv.14.11.1730
10.1161/01.atv.14.11.1730
A prospective study of lipoprotein (a) and the risk of myocardial infarction
10.1001/jama.1993.03510180065035 · 1993
10.1093/clinchem/36.1.20
10.1093/clinchem/36.1.20
10.1136/bmj.301.6763.1248
10.1136/bmj.301.6763.1248
Lipoprotein (a) in women twins: heritability and relationship to apolipoprotein (a) phenotypes
1992
10.1042/bst0210499
10.1042/bst0210499
10.1161/01.atv.14.9.1405
10.1161/01.atv.14.9.1405
10.1126/science.2530631
10.1126/science.2530631
for the American Diabetes Association. Diabetic nephropathy
1999
10.1056/nejm199611283352203
10.1056/nejm199611283352203
Unresolved referenced work
Kept as external metadata until matched
Screening for type 2 diabetes
1999
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus–Provisional report of a WHO consultation
1998
10.1016/s0140-6736(98)00021-x
10.1016/s0140-6736(98)00021-x
10.1016/0002-8703(85)90224-8
10.1016/0002-8703(85)90224-8
10.1016/s0140-6736(97)90024-6
10.1016/s0140-6736(97)90024-6
10.1016/s0022-2275(20)38659-4
10.1016/s0022-2275(20)38659-4
10.1073/pnas.91.9.3662
10.1073/pnas.91.9.3662
Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?
10.1001/jama.1990.03440210043030 · 1990
10.2337/diab.37.12.1595
10.2337/diab.37.12.1595
10.3109/07853899209166998
10.3109/07853899209166998
10.1097/00041433-199306000-00004
10.1097/00041433-199306000-00004
10.1126/science.1439783
10.1126/science.1439783
10.1056/nejm199610033351401
10.1056/nejm199610033351401 · doi-reference
10.1053/euhj.1998.1243
10.1053/euhj.1998.1243 · doi-reference
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes
10.1136/bmj.317.7160.713 · doi-reference
10.1097/00004872-199303000-00012
10.1097/00004872-199303000-00012 · doi-reference
Effects of hypoglycemic agents on vascular complications in patients with adult‐onset diabetes VII. mortality and selected nonfatal events with insulin treatment
10.1001/jama.1978.03290010041020 · doi-reference
Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
10.1016/s0140-6736(98)07019-6 · doi-reference
10.1056/nejm199309303291401
10.1056/nejm199309303291401 · doi-reference
10.1136/hrt.81.1.10
10.1136/hrt.81.1.10 · doi-reference
10.1016/0002-9149(93)90905-r
10.1016/0002-9149(93)90905-r · doi-reference
10.1016/0895-4356(94)00191-r
10.1016/0895-4356(94)00191-r · doi-reference
10.1177/107424849600100204
10.1177/107424849600100204 · doi-reference
10.1001/jama.1996.03530260042029
10.1001/jama.1996.03530260042029 · doi-reference
10.1056/nejm199511163332001
10.1056/nejm199511163332001 · doi-reference
10.1016/s0002-9149(97)00280-4
10.1016/s0002-9149(97)00280-4 · doi-reference
10.1016/s0002-9149(99)80478-0
10.1016/s0002-9149(99)80478-0 · doi-reference
10.1161/01.atv.15.5.678
10.1161/01.atv.15.5.678 · doi-reference
10.1016/s0002-9149(98)00041-1
10.1016/s0002-9149(98)00041-1 · doi-reference
10.1016/s0002-9149(97)00965-x
10.1016/s0002-9149(97)00965-x · doi-reference
Summary of the second report of the national‐cholesterol‐education‐program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
10.1001/jama.1993.03500230097036 · doi-reference
10.1056/nejm199807233390404
10.1056/nejm199807233390404 · doi-reference
10.2337/diacare.15.7.820
10.2337/diacare.15.7.820 · doi-reference
10.1056/nejm198711123172001
10.1056/nejm198711123172001 · doi-reference
10.1161/01.cir.98.23.2513
10.1161/01.cir.98.23.2513 · doi-reference
10.2337/diacare.20.4.614
10.2337/diacare.20.4.614 · doi-reference
10.1172/jci117252
10.1172/jci117252 · doi-reference
10.1016/0168-8227(95)01064-k
10.1016/0168-8227(95)01064-k · doi-reference